Antidiabetic formulation and method

Details for Australian Patent Application No. 2002357095 (hide)

Owner Bristol-Myers Squibb Company

Inventors Phusanti, Lawan; Desai, Divyakant, S.; Li, Danping

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2002357095

PCT Number PCT/US02/39140

PCT Pub. Number WO2003/051293

Priority 10/023,533 17.12.01 US

Filing date 9 December 2002

Wipo publication date 30 June 2003

Acceptance publication date 27 September 2007

International Classifications

A61K 9/20 (2006.01) Medicinal preparations characterised by special physical form - Pills, lozenges or tablets

A61K 9/28 (2006.01) Medicinal preparations characterised by special physical form - Dragees

A61K 31/155 (2006.01) - Amidines (), e.g. guanidine (HNC(NH)NH), isourea (HNC(OH)NH), isothiourea (HNC(SH)NH)

A61K 31/64 (2006.01) - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

Event Publications

27 March 2003 Complete Application Filed

  Priority application(s): 10/023,533 17.12.01 US

28 August 2003 Application Open to Public Inspection

  Published as AU-B-2002357095

27 September 2007 Application Accepted

  Published as AU-B-2002357095

24 January 2008 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002357096-Methods of increasing endogenous erythropoietin (EPO)

2002357094-Automatic electroporation optimization system